Idiopathic Pulmonary Fibrosis (IPF): An Overview Shaney L. Barratt 1,2,*, Andrew Creamer 1, Conal Hayton 3 and Nazia Chaudhuri 3 1 Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol BS10 5NB, UK;andrew.creamer@nbt.nhs.uk2 Academic Respiratory Unit, University of Bristol, Bristol BS16 1QY, UK3 North West Interstitial Lung Disease Unit, Manchester University NHS Foundation Trust, […]
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 | ||
#BreathingLife #CurePF #PFMonth #pulmonaryfibrosis #UseYourLungs Action for Pulmonary Fibrosis anti-fibrotic properties Antifibrotic therapies CD1d molecules Exercise Exercise-based pulmonary rehabilitation Exercise training fibroblasts Fibrosing interstitial pneumonia fibrosis Flattened thoracic cage Forced vital capacity FVC Idiopathic pulmonary fibrosis Interstitial lung disease IPF Macrophages Metformin’s anti-fibrotic properties Nationwide cohort study NKT Pleuroparenchymal fibroelastosis Pneumothorax PPFE Pulmonary Fibrosis Pulmonary Fibrosis Research and Education Hub Pulmonary rehabilitation Serum Krebs von den Lungen-6 T2DM tissue fibrosis Type 2 diabetes mellitus Upper lobe fibroelastosis